Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pivotal Therapeutics has started a double blind and randomized clinical marketing trials to evaluate the effectiveness of its omega-3 product Vascazen.
Subscribe to our email newsletter
Vascazen is a prescription medical food formulated to meet the dietary omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.
The company intends to complete the third-party researched trial in August 2011 in the US.
Pivotal Therapeutics expects to introduce Vascazen in Canada in October and in the US in November this year.
Pivotal Therapeutics chief scientific officer & chair George Jackowski said it is their goal to increase access and treatment options for cardiovascular patients and they are awaiting the Clinical Trial results and look forward to publishing the outcomes.